clinical trial · NCT06794268
A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company·—·recruiting·n = 300
Follicular LymphomaLisocabtagene maraleucel
brief summary
The purpose of this study is to characterise the long-term safety of lisocabtagene maraleucel, focusing on patients treated in the approved follicular lymphoma (FL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities
started
Feb 4, 2025
primary completion
Aug 31, 2044
completion
Aug 31, 2044
last updated
Feb 24, 2025
official title
Non-interventional Cohort Study of Patients Treated With Liso-cel (Lisocabtagene Maraleucel) for Relapsed/Refractory Follicular Lymphoma in the Postmarketing Setting
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol